ReviewFrontiers in public health2026
Expanding HPV prevention across the life course: evidence on vaccine effectiveness in adults.
Review in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite Human Papillomavirus (HPV) remaining a major global public health concern and affecting all age groups and genders, most HPV vaccination programmes mainly target female adolescents. This narrative review synthesizes and critically discusses recent evidence on the effectiveness of HPV vaccination among adults to inform its integration into adult immunization programmes. A substantial body of recent literature has examined the effectiveness of HPV vaccination in adult populations. Across the literature, vaccine effectiveness has been evaluated in relation to (1) HPV infection and viral dynamics, (2) precancerous cervical lesions (HSIL/CIN), (3) prevention of post-treatment recurrence, (4) HPV-related cancers, and (5) anogenital warts. Some associations were found between HPV vaccination and reduced HPV infection and viral persistence, whilst effect estimates varied widely across studies for high-grade cervical lesions (CIN2+). This review aims to characterize the effectiveness of the HPV vaccination amongst adults (18-45 years) in preventing human papillomavirus infections and HPV related disease outcomes. By synthesizing and evaluating recent evidence on HPV vaccine efficacy, we aim to assess its relevance in expanding HPV vaccination within life-course immunization programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.